NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures
Advance Novel Immuno-Oncology Programs
12-Jan-2023 -
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. The ...
cancer
cancer therapy
immuno-oncology
+1